Lumateperone in the Treatment of Stuttering, Childhood Onset Fluency Disorder

The primary objective of this study is to evaluate the efficacy and tolerability of Lumateperone in reducing stuttering symptoms. The following scales and samples will be collected for clinical and functional outcomes. • MLGSSS • SSS • Stuttering Severity Instrument (SSI-IV) • PHQ-9 • Barnes Akathisia • SAS • AIMS • CGI-I • CGI-S

NCT Number	NCT07734103
Lead Sponsor	CSTrials Inc.
Conditions	Stuttering, Adult
Enrollment	24 participants
Start Date	2026-04-18
Primary Completion	2027-07-31 (estimated)
Study Completion	2027-10-31 (estimated)
Updated on ClinicalTrials.gov	2026-07-29